eBulletin Newsletter

NCCN Flash Updates: NCCN Guidelines Updated for Esophageal and Esophagogastric Junction Cancers

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®), and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Esophageal and Esophagogastric Junction Cancers. These NCCN Guidelines^® are currently available as Version 2.2024.

Link directly to the Updates section of the NCCN Guidelines: Esophageal and Esophagogastric Junction Cancers

Squamous Cell Carcinoma

Principles of Systemic Therapy for Unresectable Locally Advanced, Recurrent or Metastatic Disease

ESOPH-F 7 of 22

• Second-line or Subsequent Therapy; Preferred regimens: Tislelizumab-jsgr was added as a category 1 recommendation.
• The corresponding footnote k is new: If prior therapy for locally advanced or metastatic ESCC did not contain checkpoint inhibitor(s).

Principles of Systemic Therapy-Regimens and Dosing Schedules

ESOPH-F 17 of 22

• Second-line or Subsequent Therapy; Preferred regimens: The following dosing schedule was added:
  • Tislelizumab-jsgr (for esophageal squamous cell carcinoma)
    200 mg IV on Day 1
    Cycled every 21 weeks

Principles of Systemic Therapy-References

ESOPH-F 22 of 22

• New references were added:
  • Ajani J, El Hajbi F, Cunningham D, et al. Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. ESMO Open 2024;9:102202.
  • Shen L, Kato K, Kim SB, et al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302) : A Randomized Phase III Study. J Clin Oncol 2022;40:3065-3076.

Previous updates to the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers can be found in the UPDATES section of the current version.

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Third Party Content: The NCCN Content may contain content (such as figures, tables or illustrations) that NCCN licenses from third parties as displayed on NCCN Third Party Content site: private.filesanywhere.com/fs/v.aspx?v=8a6d65cfa19ea4bda0a3&C=6241. Licensee shall be solely responsible for obtaining permissions from each such third party to use any such Third Party Content in the Permitted Works. 

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.